GBT Quote, Trading Chart, Global Blood Therapeutics Inc.

$40.28 Last:

-0.89% Change Percent:

$41 Open:

$40.28 Previous Close:

$41.23 High:

$39.98 Low:

970,764 Volume:

06/14/2021 04:42:48 am Last Trade Date Time:

Quotes are delayed by 15 to 20 minutes.

Stock Date	Open Price	Close Price	High	Low	Volume
2021-06-14	41	40.28	41.23	39.98	970,764
2021-06-11	41.72	40.64	41.72	40.1	938,660
2021-06-10	40.42	41.67	41.72	39.86	1,102,796
2021-06-09	41.36	40.42	41.73	40.2137	754,138
2021-06-08	40.05	40.65	40.73	39.4	825,316
2021-06-07	39.04	39.85	40.09	38.26	949,190
2021-06-04	38.48	39	39.77	38.03	729,955
2021-06-03	37.6	38.26	38.38	37.14	582,873
2021-06-02	37.2	37.56	37.64	36.42	814,838
2021-06-01	38.32	37.2	38.383	37.02	843,520
2021-05-31	38.94	38.43	39.93	38.32	730,604
2021-05-28	38.94	38.43	39.93	38.32	727,479
2021-05-27	39.02	38.78	39.33	38.21	633,397
2021-05-26	38.25	39.21	39.38	38.1	586,839
2021-05-25	37.24	38.12	38.235	36.9532	644,326
2021-05-24	38.01	37.23	38.4839	37.15	471,913
2021-05-21	37.85	37.8	38.31	36.61	553,403
2021-05-20	36.47	37.74	38.31	36.47	563,847
2021-05-19	36.82	36.43	37.22	36.01	628,097
2021-05-18	36.38	37.29	38.24	36.04	915,585

Stock Information

Global Blood Therapeutics Inc. Company Name:

GBT Stock Symbol:

NASDAQ Market:

Get GBT Alerts

News, Short Squeeze, Breakout and More Instantly...

GBT - GBT's Voxelotor is First Sickle Cell Disease Treatment to Receive Promising Innovative Medicine (PIM) Designation in the UK

SOUTH SAN FRANCISCO, Calif. and LONDON, June 14, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments for underserved patient communities, announced toda...
GBT - New Data Supporting the Potential Use of Oxbryta® (voxelotor) in Children Ages 4 to 11 Years with Sickle Cell Disease Presented at European Hematology Association 2021 Virtual Congress

Analysis from Phase 2a HOPE-KIDS 1 Study Featured in Oral Presentation Two Real-world Data Studies Demonstrated Sustained Improvements in Hemoglobin with Oxbryta Consistent with Results from the Phase 3 HOPE Study SOUTH SAN FRANCISCO, Calif., June 11, 2021 (GLOBE NEWSWIRE)...
GBT - GBT Announces Participation at the Goldman Sachs 42nd Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the 42nd Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 8, 2021, at 2:10 p.m...